Clinical Trials on Adult T-cell Leukemia/lymphoma in United States

Total 4968 results

King's College Hospital NHS Trust

Completed

Pilot Study of Combination Therapy With CHOP-Zenapax (CHOP-daclizumab)

HTLV-I Associated Adult T-cell Leukaemia/Lymphoma (ATLL)

United Kingdom
University of Alabama at Birmingham

Terminated

Lenalidomide Therapy for Patients With Relapsed and/or Refractory, Peripheral T-Cell Lymphomas

Anaplastic Large Cell Lymphoma | Angioimmunoblastic T-cell Lymphoma | Peripheral T-cell Lymphomas | Adult T-cell Leukemia | Adult T-cell Lymphoma | Peripheral T-cell Lymphoma Unspecified | T/Null Cell Systemic Type | Cutaneous t-Cell Lymphoma With Nodal/Visceral Disease

United States
Columbia University
Celgene Corporation

Completed

Lenalidomide in HTLV-1 Adult T-Cell Leukemia

Adult T Cell Leukemia/Lymphoma

United States
UNC Lineberger Comprehensive Cancer Center
Seagen Inc.

Active, not recruiting

BV-CHEP Chemotherapy for Adult T-cell Leukemia or Lymphoma

Lymphoma | Lymphatic Diseases | Adult T-Cell Leukemia/Lymphoma

United States
National Cancer Institute (NCI)

Completed

Phase I Study of Recombinant Human IL-15 (rhIL-15) and Mogamulizumab for People With Refractory or Relapsed Adult T-Cell Leukemia and Mycosis Fungoides/Sezary Syndrome

Mycosis Fungoides | Sezary Syndrome | Adult T-Cell Lymphoma/Leukemia

United States
National Cancer Institute (NCI)

Completed

Subcutaneous Recombinant Human IL-15 (s.c. rhIL-15) and Alemtuzumab for People With Refractory or Relapsed Chronic and Acute Adult T-cell Leukemia (ATL)

Peripheral T-Cell Lymphoma (PTCL) | T-Cell Prolymphocytic Leukemia | Cutaneous T Cell Lymphoma (CTCL) | T-Cell Lymphoma Relapsed | Adult T-Cell Leukemia (ATL)

United States
Amit Verma

Terminated

A Phase II Study Of Imtox-25 In Adults With Refractory/Relapsed Cd25 Positive Adult T Cell Leukemia/Lymphoma

Adult T Cell Leukemia | Adult T Cell Lymphoma

United States
National Cancer Institute (NCI)

Completed

Nivolumab in Treating Patients With HTLV-Associated T-Cell Leukemia/Lymphoma

Acute Adult T-Cell Leukemia/Lymphoma | Adult T-Cell Leukemia/Lymphoma | Chronic Adult T-Cell Leukemia/Lymphoma | HTLV-1 Infection | Lymphomatous Adult T-Cell Leukemia/Lymphoma | Smoldering Adult T-Cell Leukemia/Lymphoma

United States
University of Miami

Recruiting

Belinostat Therapy With Zidovudine for Adult T-Cell Leukemia-Lymphoma

Adult T-cell Leukemia-Lymphoma | ATLL

United States
National Cancer Institute (NCI)

Completed

Treatment of Tac-Expressing Cutaneous T-Cell Lymphoma (CTCL) and Adult T-Cell Leukemia (ATL) With Yttrium-90 Radiolabeled Anti-Tac

Lymphoma, T-Cell, Cutaneous | Leukemia, T-Cell

United States
John Reneau

Recruiting

Third-Party Natural Killer Cells and Mogamulizumab for the Treatment of Relapsed or Refractory Cutaneous T-cell Lymphomas or Adult T-Cell Leukemia/Lymphoma

Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma | Recurrent Adult T-Cell Leukemia/Lymphoma | Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma | Refractory Adult T-Cell Leukemia/Lymphoma

United States
National Cancer Institute (NCI)

Withdrawn

Doxorubicin, CC-(486) (5-azacitidine), Romidepsin, and Duvelisib (hARD) for T-cell Lymphoma

Hepatosplenic T-cell Lymphoma | Enteropathy-Associated T-Cell Lymphoma | Adult T-cell Leukemia/Lymphoma | Extranodal NK-/T-cell Lymphoma, Nasal Type | Monomorphic Epiteliotrophic Intestinal T-cell Lymphoma

United States
Kyowa Kirin, Inc.

Completed

KW-0761 or Investigator's Choice in Subjects With Previously Treated Adult T-cell Leukemia-Lymphoma (ATL)

Adult T-cell Leukemia-Lymphoma

United States, United Kingdom, Belgium, France, Brazil, Peru
University of Nebraska
National Cancer Institute (NCI); Amgen

Completed

Carfilzomib in Treating Patients With Relapsed or Refractory T-Cell Lymphoma

Peripheral T-cell Lymphoma | Anaplastic Large Cell Lymphoma | Angioimmunoblastic T-cell Lymphoma | Adult Nasal Type Extranodal NK/T-cell Lymphoma | Recurrent Adult T-cell Leukemia/Lymphoma

United States
Deepa Jagadeesh

Recruiting

A Phase II Study of Single Agent Brentuximab Vedotin in Relapsed/Refractory CD30 Low (<10%) Mature T Cell Lymphoma (TCL)

Angioimmunoblastic T-cell Lymphoma | T-cell Lymphoma | Adult T-cell Leukemia/Lymphoma | Enteropathy Associated T-cell Lymphoma | Hepato-splenic T-cell Lymphoma | NK T-cell Lymphoma

United States
National Cancer Institute (NCI)

Completed

Campath-1H for Treating Adult T-Cell Leukemia/Lymphoma

Acute T-Cell Leukemia-Lymphoma

United States
Wake Forest University Health Sciences
National Cancer Institute (NCI)

Completed

CPI-613 and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma or Hodgkin Lymphoma

Peripheral T-cell Lymphoma | Anaplastic Large Cell Lymphoma | Angioimmunoblastic T-cell Lymphoma | Adult Nasal Type Extranodal NK/T-cell Lymphoma | Hepatosplenic T-cell Lymphoma | Recurrent Adult Acute Lymphoblastic Leukemia | Recurrent Adult Hodgkin Lymphoma | Recurrent Adult T-cell Leukemia/Lymphoma and other conditions

United States
AIDS Malignancy Consortium
National Cancer Institute (NCI)

Completed

Combination Chemotherapy Followed By Antiviral Therapy and Interferon Alfa in Treating Patients With HTLV-1-Related Adult T-Cell Leukemia/Lymphoma

Lymphoma

United States
Daiichi Sankyo

Active, not recruiting

Valemetostat Tosylate (DS-3201b), an Enhancer of Zeste Homolog (EZH) 1/2 Dual Inhibitor, for Relapsed/Refractory Peripheral T-Cell Lymphoma (VALENTINE-PTCL01)

Relapsed/Refractory Peripheral T-Cell Lymphoma | Adult T Cell Leukemia/Lymphoma

United States, Spain, Japan, United Kingdom, Korea, Republic of, France, Italy, Australia, Canada, Germany, Netherlands, Taiwan
University of Miami
National Cancer Institute (NCI)

Terminated

Zidovudine, Interferon Alfa-2b, PEG-Interferon Alfa-2b in Patients With HTLV-I Associated Adult T-Cell Leukemia/Lymphoma

Lymphoma | Precancerous/Nonmalignant Condition

United States
National Cancer Institute (NCI)

Completed

Phase II Trial of LMB-2, Fludarabine and Cyclophosphamide for Adult T-Cell Leukemia

Adult T-Cell Leukemia (ATL)

United States
National Cancer Institute (NCI)

Terminated

Phase II Study of the Efficacy and Toxicity of Ontak(Registered Trademark) (Denileukin Diftitox) in the Therapy of Adult T-Cell Leukemia

Leukemia, Adult T-Cell

United States
Washington University School of Medicine
Wugen, Inc.

Recruiting

Dose-Escalation and Dose-Expansion Study to Evaluate the Safety and Tolerability of Anti-CD7 Allogeneic CAR T-Cells (WU-CART-007) in Patients With CD7+ Hematologic Malignancies

Acute Myeloid Leukemia | Sezary Syndrome | Anaplastic Large Cell Lymphoma | Angioimmunoblastic T-cell Lymphoma | Adult T Cell Leukemia | Adult T Cell Lymphoma | Hepatosplenic T-cell Lymphoma | Peripheral T Cell Lymphoma | Extranodal NK/T-cell Lymphoma | Enteropathy-Associated T-Cell Lymphoma | T-Cell Non-Hodgkin... and other conditions

United States
National Cancer Institute (NCI)

Recruiting

Testing the Addition of an Anti-cancer Drug, Lenalidomide, to the Usual Combination Chemotherapy Treatment ("EPOCH") for Adult T-Cell Leukemia-Lymphoma (ATL)

Acute Adult T-Cell Leukemia/Lymphoma | Adult T-Cell Leukemia/Lymphoma | Chronic Adult T-Cell Leukemia/Lymphoma | HTLV-1 Infection

United States
National Cancer Institute (NCI)

Terminated

Ruxolitinib for Adult T-Cell Leukemia

Leukemia, Adult T-Cell | T Cell Leukemia, Adult | T Cell Leukemia, HTLV I Associated

United States
National Cancer Institute (NCI)

Completed

Study of Adult T-Cell Leukemia/Lymphoma Among Carriers of HTLV-1

Human T-Lymphoma Virus Type I

United States, Jamaica, Japan
Sidney Kimmel Cancer Center at Thomas Jefferson...
American Society of Clinical Oncology

Completed

A Pilot Study to Determine the Safety and Tolerability of Sirolimus Given With Hyper-CVAD Chemotherapy

Burkitt Lymphoma | Acute Lymphoblastic Leukemia | Lymphoblastic Lymphoma | Mantle Cell Lymphoma | Lymphoid Malignancies (New or Relapsed) | Adult T-cell Leukemia/Lymphoma

United States
National Cancer Institute (NCI)

Recruiting

Collection of Human Samples to Study Hairy Cell and Other Leukemias, and to Develop Recombinant Immunotoxins for Cancer Treatment

Chronic Lymphocytic Leukemia (CLL) | Hairy Cell Leukemia (HCL) | Cutaneous T Cell Lymphoma (CTCL) | Non-Hodgkins Lymphoma (NHL) | Adult T Cell Lymphoma (ATL)

United States
National Cancer Institute (NCI)

Completed

Sorafenib Tosylate in Treating Patients With Recurrent Aggressive Non-Hodgkin's Lymphoma

Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Adult Immunoblastic Large Cell Lymphoma | Peripheral T-cell Lymphoma | Anaplastic Large Cell Lymphoma | Angioimmunoblastic T-cell Lymphoma | Hepatosplenic T-cell Lymphoma | Recurrent Adult T-cell Leukemia/Lymphoma | Recurrent Cutaneous T-cell...

United States
Juan C. Ramos, MD

Withdrawn

Safety Trial of STING-dependent Activators and Stimulated Dendritic Cells for Aggressive Relapsed/Refractory Leukemias

Acute Lymphoblastic Leukemia | Acute Myelogenous Leukemia | Refractory Leukemia | Adult T-Cell Leukemia/Lymphoma | Relapsed Leukemia

United States
National Cancer Institute (NCI)

Completed

Alisertib in Treating Patients With Relapsed or Refractory Peripheral T-Cell Non-Hodgkin Lymphoma

Anaplastic Large Cell Lymphoma | Recurrent Adult Non-Hodgkin Lymphoma | Angioimmunoblastic T-Cell Lymphoma | Hepatosplenic T-Cell Lymphoma | Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma | Recurrent Adult T-Cell Leukemia/Lymphoma | Adult Nasal Type Extranodal NK/T-Cell Lymphoma

United States, Canada
Pierluigi Porcu
Millennium Pharmaceuticals, Inc.; Celgene Corporation

Completed

Bortezomib and Azacitidine in Treating Patients With Relapsed or Refractory T-Cell Lymphoma

Peripheral T-cell Lymphoma | Anaplastic Large Cell Lymphoma | Angioimmunoblastic T-cell Lymphoma | Adult Nasal Type Extranodal NK/T-cell Lymphoma | Hepatosplenic T-cell Lymphoma | Post-transplant Lymphoproliferative Disorder | Recurrent Adult T-cell Leukemia/Lymphoma | Recurrent Cutaneous T-cell... and other conditions

United States
National Cancer Institute (NCI)

Completed

Study of Akt Inhibitor MK2206 in Patients With Relapsed Lymphoma

Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Adult Diffuse Mixed Cell Lymphoma | Recurrent Adult Diffuse Small Cleaved Cell Lymphoma | Recurrent Adult Immunoblastic... and other conditions

United States
miRagen Therapeutics, Inc.

Completed

Safety, Tolerability and Pharmacokinetics of MRG-106 in Patients With Mycosis Fungoides (MF), CLL, DLBCL or ATLL

Chronic Lymphocytic Leukemia (CLL) | Cutaneous T-cell Lymphoma (CTCL) | Mycosis Fungoides (MF) | Diffuse Large B-Cell Lymphoma (DLBCL), ABC Subtype | Adult T-Cell Leukemia/Lymphoma (ATLL)

United States
National Cancer Institute (NCI)

Completed

Monoclonal Antibody Therapy in Treating Patients With Leukemia

Lymphoma | Radiation Toxicity

United States
Robert Lowsky
National Cancer Institute (NCI)

Completed

Donor Peripheral Stem Cell Transplant in Treating Patients With Hematolymphoid Malignancies

Recurrent Adult Acute Myeloid Leukemia | Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Burkitt Lymphoma | Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Adult Diffuse Mixed Cell Lymphoma | Recurrent Adult Diffuse Small Cleaved Cell Lymphoma | Recurrent Adult Immunoblastic Large... and other conditions

United States
Mayo Clinic
National Cancer Institute (NCI)

Completed

Panobinostat and Everolimus in Treating Patients With Recurrent Multiple Myeloma, Non-Hodgkin Lymphoma, or Hodgkin Lymphoma

Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Burkitt Lymphoma | Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Adult Lymphoblastic Lymphoma | Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade... and other conditions

United States
Case Comprehensive Cancer Center
National Cancer Institute (NCI)

Terminated

Etoposide, Filgrastim, and Plerixafor in Improving Stem Cell Mobilization in Treating Patients With Non-Hodgkin Lymphoma

Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Burkitt Lymphoma | Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Adult Diffuse Mixed Cell Lymphoma | Recurrent Adult Diffuse Small Cleaved Cell Lymphoma and other conditions

United States
National Cancer Institute (NCI)

Completed

Tipifarnib in Treating Patients With Relapsed or Refractory Lymphoma

Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Grade 3 Follicular Lymphoma | Recurrent Mantle Cell Lymphoma | Splenic Marginal Zone Lymphoma | Anaplastic Large Cell Lymphoma | Recurrent Adult Hodgkin Lymphoma | Recurrent Small Lymphocytic Lymphoma | Recurrent... and other conditions

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Terminated

Lenalidomide With or Without Rituximab in Treating Patients With Progressive or Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Prolymphocytic Leukemia, or Non-Hodgkin Lymphoma Previously Treated With Donor Stem Cell Transplant

Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Burkitt Lymphoma | Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Adult Diffuse Mixed Cell Lymphoma | Recurrent Adult Diffuse Small Cleaved Cell Lymphoma and other conditions

United States
Memorial Sloan Kettering Cancer Center

Active, not recruiting

A Study of Ruxolitinib and Duvelisib in People With Lymphoma

T-cell Large Granular Lymphocyte Leukemia | T-cell Lymphomas | T-cell Prolymphocytic Leukemia | NK-Cell Lymphomas

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Terminated

Monoclonal Antibody Therapy Before Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoid Malignancies

Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Burkitt Lymphoma | Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Adult Diffuse Mixed Cell Lymphoma | Recurrent Adult Diffuse Small Cleaved Cell Lymphoma and other conditions

United States
National Cancer Institute (NCI)

Completed

Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid Tumors

Recurrent Adult Burkitt Lymphoma | Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Adult Diffuse Mixed Cell Lymphoma | Recurrent Adult Diffuse Small Cleaved Cell Lymphoma | Recurrent Adult Lymphoblastic Lymphoma | Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma and other conditions

United States
National Cancer Institute (NCI)

Terminated

Oblimersen and Gemcitabine in Treating Patients With Advanced Solid Tumor or Lymphoma

Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Burkitt Lymphoma | Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Adult Diffuse Mixed Cell Lymphoma | Recurrent Adult Diffuse Small Cleaved Cell Lymphoma and other conditions

United States
Washington University School of Medicine

Completed

EPOCH Chemotherapy and Bortezomib for Associated T-Cell Leukemia Lymphoma (ATLL)

Leukemia-Lymphoma, Adult T-Cell

United States
Case Comprehensive Cancer Center
National Cancer Institute (NCI)

Completed

Methoxyamine and Fludarabine Phosphate in Treating Patients With Relapsed or Refractory Hematologic Malignancies

Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Burkitt Lymphoma | Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Adult Diffuse Mixed Cell Lymphoma | Recurrent Adult Diffuse Small Cleaved Cell Lymphoma and other conditions

United States
Mayo Clinic
National Cancer Institute (NCI)

Terminated

Nivolumab in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma

Blastic Plasmacytoid Dendritic Cell Neoplasm | HTLV-1 Infection | Recurrent Mycosis Fungoides | Refractory Mycosis Fungoides | Refractory Angioimmunoblastic T-cell Lymphoma | Hepatosplenic T-Cell Lymphoma | Recurrent Adult T-Cell Leukemia/Lymphoma | Refractory Anaplastic Large Cell Lymphoma | Recurrent... and other conditions

United States
National Cancer Institute (NCI)

Terminated

17-N-Allylamino-17-Demethoxygeldanamycin and Bortezomib in Treating Patients With Relapsed or Refractory Hematologic Cancer

Recurrent Adult Acute Myeloid Leukemia | Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent... and other conditions

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Haploidentical Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancer

Stage II Multiple Myeloma | Stage III Multiple Myeloma | Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Burkitt Lymphoma | Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Adult Diffuse Mixed Cell Lymphoma and other conditions

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Active, not recruiting

Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With CD30-Positive Peripheral T-cell Lymphoma

Anaplastic Large Cell Lymphoma, ALK-Positive | Adult T-Cell Leukemia/Lymphoma | Angioimmunoblastic T-Cell Lymphoma | Hepatosplenic T-Cell Lymphoma | Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma | Enteropathy-Associated T-Cell Lymphoma | Peripheral T-Cell Lymphoma, Not Otherwise Specified | Anaplastic... and other conditions

United States, Canada

Clinical Trials on Adult T-cell Leukemia/lymphoma in United States

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Ukraine

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations